The nevadensin-treated HCC cells significantly phosphorylated and activated MST1/2-LATS1/2, phosphorylated and inactivated Merlin, and enhanced the activity of the Hippo pathway to inhibit the YAP/TAZ activity, eventually inhibiting the growth of HCC cells. The gene discussed is NF2; the disease is hepatocellular carcinoma.